The most valuable breakthroughs in drug development come from finding the right direction before picking up speed. In this episode, Viwat Visuthikraisee, Co-Founder and COO of Auransa, discusses his journey from studying theoretical physics in Japan to building an AI-driven biotech company in the Bay Area. His early fascination with computers led to a career in software and, ultimately, to applying computational power to biopharma using human-derived molecular data to identify promising drug candidates early. He reflects on the role of large language models like ChatGPT as productivity tools that expand human capabilities without immediately replacing core programming skills. Viwat also discusses the challenges of drug discovery and advises founders to raise funds whenever possible, build the right team, and focus on long-term success. Tune in and learn how AI is transforming drug discovery, why direction matters more than speed, and what it takes to lead innovation in a high-stakes industry Resources: Follow Auransa on LinkedIn and visit their website.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related